⚕ GalenOps CRO console
← SITE013 (USA)

SITE013-0027

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE013 (USA) (Dr. Clarke) · consented 2022-03-18
Adverse events
8
Serious AEs
2
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-01 (study day 88); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 95); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 140); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 228); relationship: not assessed; serious criteria: hospitalization

severe serious assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 279); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-30 (study day 421); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-21 (study day 565); relationship: N

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-26 (study day 601); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.